REG - AstraZeneca PLC - Final Results <Origin Href="QuoteRef">AZN.L</Origin> - Part 4

AstraZenecaAnnouncement

05/02/2015 07:11

- Part 4: For the preceding part double click  ID:nRSE1189Ec 

                                   Q4 2012               H2 2016           H2 2016   H2 2016  H2 2016  
 Respiratory, Inflammation and Autoimmunity  
 Duaklir Genuair                             LAMA / LABA                                                      COPD                                                                                                                                                              Approved                    
 SymbicortSYGMA-1                            ICS / LABA                                                       as needed use in mild asthma                                                                                              Q4 2014               N/A               2018                        
 Symbicort5                                  ICS / LABA                                                       Breath Actuated Inhaler asthma / COPD                                                                                                                                                         
 
 
Significant Life-Cycle Management (continued) 
 
 Compound          Mechanism                      Area Under Investigation                    Date Commenced Phase  Estimated Filing  
 US                EU                             Japan                                       China                 
 Neuroscience      
 Diprivan#         sedative and anaesthetic       conscious sedation                                                N/A               Launched  Filed    Launched  
 Gastrointestinal  
 Entocort          glucocorticoid steroid         Crohn's disease / ulcerative colitis                              Launched          Launched  Q3 2015  N/A       
 linaclotide#      GC-C receptor peptide agonist  irritable bowel syndrome with constipation                        N/A               N/A       N/A      Q4 2015   
                                                  (IBS-C)                                                                                                          
 Nexium            proton pump inhibitor          refractory reflux esophagitis                                                                 Filed              
 Nexium            proton pump inhibitor          stress ulcer prophylaxis                                                                               2017      
 Nexium            proton pump inhibitor          paediatrics                                                       Launched          Launched  H2 2016            
 
 
#    Partnered product. 
 
1    Brilinta in the US; Brilique in rest of world. 
 
2    Farxiga in the US; Forxiga in rest of world. 
 
3    Kombiglyze XR in the US; Komboglyze FDC in the EU. 
 
4    Xigduo XR FDC in the US; Xigduo FDC in the EU. 
 
5    Development of a new BAI device is ongoing. 
 
6    Submission made in US in December 2014, acceptance anticipated Q1 2015 
 
Terminations (discontinued projects between 1 October and 31 December 2014) 
 
 NME / Line Extension  Compound  Reason for Discontinuation  Area Under Investigation  
 NME                   AZD1979   Safety / efficacy           obesity                   
 NME                   AZD6423   Safety / efficacy           suicidal ideation         
 
 
#    Partnered product. 
 
Shareholder Information 
 
ANNOUNCEMENTS AND MEETINGS 
 

______________________________________________________________________________________________________________________________________________________________________________________________________________________________ 
 
Announcement of first quarter 2015 results                                                       24 April 2015 
 
Annual General Meeting                                                                                    24 April 2015 
 
Announcement of second quarter and half year 2014 results                           30 July 2015 
 
Announcement of third quarter and nine months 2014 results                          5 November 2015 
 
DIVIDENDS 
 

______________________________________________________________________________________________________________________________________________________________________________________________________________________________ 
 
The record date for the first interim dividend, paid on 15 September 2014, was 15 August 2014. Shares traded ex-dividend
from 13 August 2014. 
 
The record date for the second interim dividend for 2014, payable on 23 March 2015, will be 20 February 2015. Ordinary
Shares listed in London and Stockholm will trade ex-dividend from 19 February 2015. American Depositary Shares listed in
New York will trade ex-dividend from 18 February 2015. 
 
Future dividends will normally be paid as follows: 
 
 First interim   Announced with second quarter and half year results and paid in September  
 Second interim  Announced with fourth quarter and full year results and paid in March      
 
 
The Company is in the process of transferring its US American Depositary Receipt (ADR) Programme to Citibank, N.A. The
Company will implement a dividend fee of $0.03 per ADR annually to cover ADR Programme costs, commencing with a fee of
$0.02 per ADR on the second interim dividend for 2014, payable on 23 March 2015. 
 
TRADEMARKS 
 

_____________________________________________________________________________________________________________________________________________________________________________________________________________________________________ 
 
Trademarks of the AstraZeneca group of companies and of companies other than AstraZeneca appear throughout this document in
italics. AstraZeneca, the AstraZeneca logotype and the AstraZeneca symbol are all trademarks of the AstraZeneca group of
companies. Trademarks of companies other than AstraZeneca that appear in this document include Duaklir Genuair, Duaklir and
Eklira, trademarks of Almirall, S.A.; Tissue Phenomics and Cognition Network Technology, trademarks of Definiens AG; and
Imbruvica, a trademark of Pharmacyclics, Inc. 
 
ADDRESSES FOR CORRESPONDENCE 
 

______________________________________________________________________________________________________________________________________________________________________________________________________________________________ 
 
 Registrar andTransfer OfficeEquiniti LimitedAspect HouseSpencer RoadLancingWest SussexBN99 6DAUK  US DepositaryJP Morgan Chase & CoPO Box 64504St PaulMN 55164-0504US   Registered Office2 Kingdom StreetLondonW2 6BDUK  Swedish Central Securities DepositoryEuroclear Sweden ABPO Box 191SE-101 23 StockholmSweden  
 Tel (freephone in UK):                                                                            Tel (toll free in US): 888 697 8018Tel (outside US): +1 651 453 2128  Tel: +44 (0) 20 7604 8000                        Tel: +46 (0)8 402 9000                                                                       
 0800 389 1580Tel (outside UK):                                                                                                                                                                                                                                                                                        
 +44 (0)121 415 7033                                                                                                                                                                                                                                                                                                   
 
 
CONTACT INFORMATION 
 

______________________________________________________________________________________________________________________________________________________________________________________________________________________________ 
 
Media Enquiries:                                 Esra Erkal-Paler (London)                                +44 (0) 20 7604
8030 
 
Vanessa Rhodes (London)                              +44 (0) 20 7604 8037 
 
Ayesha Bharmal (London)                                +44 (0) 20 7604 8034 
 
Jacob Lund (Södertälje)                                    +46 (0) 8 553 260 20 
 
Analyst/Investor Enquiries:                Thomas Kudsk Larsen (London)                    +44 (0) 20 7604 8199 
 
Karl Hård (London)                                            +44 (0) 20 7604 8123 
 
Eugenia Litz (London)                                       +44 (0) 20 7604 8233 
 
Craig Marks (London)                                       +44 (0) 20 7604 8591 
 
Christer Gruvris (London)                                 +44 (0) 20 7604 8126 
 
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS 
 

______________________________________________________________________________________________________________________________________________________________________________________________________________________________ 
 
In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act
1995, we are providing the following cautionary statement: The preliminary announcement contains certain forward-looking
statements with respect to the operations, performance and financial condition of the Group. Although we believe our
expectations are based on reasonable assumptions, any forward-looking statements, by their very nature, involve risks and
uncertainties and may be influenced by factors that could cause actual outcomes and results to be materially different from
those predicted. The forward-looking statements reflect knowledge and information available at the date of preparation of
the preliminary announcement and AstraZeneca undertakes no obligation to update these forward-looking statements. We
identify the forward-looking statements by using the words 'anticipates', 'believes', 'expects', 'intends' and similar
expressions in such statements. Important factors that could cause actual results to differ materially from those contained
in forward-looking statements, certain of which are beyond our control, include, among other things: the loss or expiration
of patents, marketing exclusivity or trademarks, or the risk of failure to obtain patent protection; the risk of
substantial adverse litigation/government investigation claims and insufficient insurance coverage; exchange rate
fluctuations; the risk that R&D will not yield new products that achieve commercial success; the risk that strategic
alliances and acquisitions will be unsuccessful; the impact of competition, price controls and price reductions; taxation
risks; the risk of substantial product liability claims; the impact of any delays in the manufacturing, distribution and
sale of any of our products; the impact of any failure by third parties to supply materials or services; the risk of
failure to manage a crisis; the risk of delay to new product launches; the difficulties of obtaining and maintaining
regulatory approvals for products; the risk of failure to observe ongoing regulatory oversight; the risk that new products
do not perform as we expect; the risk of environmental liabilities; the risks associated with conducting business in
emerging markets; the risk of reputational damage; the risk of product counterfeiting; the risk of failure to successfully
implement planned cost reduction measures through productivity initiatives and restructuring programmes; the risk that
regulatory approval processes for biosimilars could have an adverse effect on future commercial prospects; the impact of
failing to attract and retain key personnel and to successfully engage with our employees; and the impact of increasing
implementation and enforcement of more stringent anti-bribery and anti-corruption legislation. 
 
This information is provided by RNS
The company news service from the London Stock Exchange